Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 1
2007 1
2008 1
2015 1
2016 2
2019 3
2020 2
2021 6
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Larkin J, et al. Among authors: moshyk a. N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562797 Free article. Clinical Trial.
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D, Tawbi H, Lipson EJ, Stephen Hodi F, Rutkowski P, Gogas H, Lao CD, Grob JJ, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV. Schadendorf D, et al. Among authors: moshyk a. Eur J Cancer. 2023 Jul;187:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22. Eur J Cancer. 2023. PMID: 37167764 Free article. Clinical Trial.
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France.
Bregman B, Teitsson S, Orsini I, Cotté FE, Amadi A, Moshyk A, Roze S, Gaudin AF. Bregman B, et al. Among authors: moshyk a. Dermatol Ther (Heidelb). 2020 Dec;10(6):1331-1343. doi: 10.1007/s13555-020-00446-z. Epub 2020 Sep 13. Dermatol Ther (Heidelb). 2020. PMID: 32920709 Free PMC article.
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.
Branchoux S, Sofeu CL, Gaudin AF, Kurt M, Moshyk A, Italiano A, Bellera C, Rondeau V. Branchoux S, et al. Among authors: moshyk a. ESMO Open. 2022 Feb;7(1):100340. doi: 10.1016/j.esmoop.2021.100340. Epub 2021 Dec 17. ESMO Open. 2022. PMID: 34929616 Free PMC article.
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆.
Tarhini AA, Toor K, Chan K, McDermott DF, Mohr P, Larkin J, Hodi FS, Lee CH, Rizzo JI, Johnson H, Moshyk A, Rao S, Kotapati S, Atkins MB. Tarhini AA, et al. Among authors: moshyk a. ESMO Open. 2021 Apr;6(2):100050. doi: 10.1016/j.esmoop.2021.100050. Epub 2021 Feb 6. ESMO Open. 2021. PMID: 33556898 Free PMC article.
Integrating feedback from a clinical data warehouse into practice organisation.
Grant A, Moshyk A, Diab H, Caron P, de Lorenzi F, Bisson G, Menard L, Lefebvre R, Gauthier P, Grondin R, Desautels M. Grant A, et al. Among authors: moshyk a. Int J Med Inform. 2006 Mar-Apr;75(3-4):232-9. doi: 10.1016/j.ijmedinf.2005.07.037. Epub 2005 Sep 8. Int J Med Inform. 2006. PMID: 16153886
23 results